晚期糖化终末产物与糖尿病视网膜病变相关性的研究进展  

The advances on the correlation between advanced glycation end-products and diabetic retinopathy

作　　者：罗桂彬 沈强 张蓝月 刘涵[1] Luo Guibin;Shen Qiang;Zhang Lanyue;Liu Han(Department of Ophthalmology,Chongqing University Jiangjin Hospital,Chongqing 402260,China)

机构地区：[1]重庆大学附属江津医院眼科,402260

出　　处：《中华眼科医学杂志（电子版）》2024年第4期247-251,共5页Chinese Journal of Ophthalmologic Medicine(Electronic Edition)

基　　金：重庆市自然科学基金面上项目(CSTB2023NSCQ-MSX1061,CSTB2023NSCQ-MSX0639);重庆市江津区科学技术局项目(Y2023016)。

摘　　要：糖尿病会引起糖尿病视网膜病变(DR),是成人失明和低视力的重要原因。晚期糖化终末产物(AGE)是由葡萄糖或其他糖类对蛋白质、脂类及核酸等大分子进行翻译后非酶修饰而产生的分子,AGE与晚期糖基化终产物受体(RAGE)结合后会产生一系列病理机制,是参与DR发生与进展的重要因素。AGE抑制剂、AGE阻滞剂及RAGE抑制剂是未来DR潜在的治疗靶点。本文中笔者就AGE与DR的相关性进行综述,旨在为DR的诊疗提供新思路。Diabetes causes diabetic retinopathy(DR),which is an important cause of blindness and low vision in adults.Advanced glycation end products(AGE)are molecules produced by non enzymatic modification of large molecules such as proteins,lipids,and nucleic acids through translation by glucose or other sugars.Binding of AGE to the receptor for advanced glycosylation end products(RAGE)can produce a series of pathological mechanisms,which are important factors involved in the occurrence and progression of DR.AGE inhibitors,AGE blockers,and RAGE inhibitors are potential therapeutic targets for DR in the future.The correlation between AGE and DR was reviewed in this paper,aiming to provide insights for the diagnosis and treatment of DR.

关 键 词：糖尿病 糖尿病视网膜病变 晚期糖化终末产物 晚期糖基化终产物受体 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]